Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial
October 20, 2021 07:00 ET
|
Synairgen plc
Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen announces its inhaled interferon beta (SNG001) is advancing to Phase 3 of the NIH-sponsored ACTIV-2 COVID-19 Trial Southampton, UK – 20 October...
Synairgen plc - Interim results for the six months ended 30 June 2020
September 29, 2020 07:00 ET
|
Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2020 Southampton, UK – 29 September 2020: Synairgen plc (LSE: SNG), the respiratory drug...
Synairgen Completes Recruitment of Hospitalised Patients in COVID-19 Trial
May 28, 2020 07:00 ET
|
Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Synairgen Completes Recruitment of Hospitalised Patients in COVID-19 Trial Southampton, UK – 28 May 2020: Synairgen plc (LSE: SNG), the...